CARCINOMA OF THE HEAD AND NECK Clinical Trials

19 clinical trials for CARCINOMA OF THE HEAD AND NECK across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 2/3 STUDY OF FICERAFUSP ALFA (BCA101) OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST LINE TREATMENT OF PD-L1-POSITIVE, RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA — RECRUITING · PHASE2
• A RANDOMIZED, PHASE 2, OPEN-LABEL, MULTI-ARM STUDY OF TISLELIZUMAB IN COMBINATION WITH INVESTIGATIONAL AGENTS AS FIRST-LINE TREATMENT IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA — RECRUITING · PHASE2
• INTRATYMPANIC N-ACETYLCYSTEINE (NAC) INJECTIONS FOR PREVENTION OF CISPLATIN-INDUCED OTOTOXICITY IN HEAD AND NECK CANCER PATIENTS: A MULTI-CENTRE PHASE II RANDOMIZED CONTROLLED TRIAL. — RECRUITING · PHASE2
• "A PHASE II, RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF MEDI4736 MONOTHERAPY, TREMELIMUMAB MONOTHERAPY, AND MEDI4736 IN COMBINATION WITH TREMELIMUMAB IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)." — RECRUITING · PHASE2
• A PHASE 3 CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) IN FIRST LINE TREATMENT OF RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA — RECRUITING · PHASE3
• RANDOMIZED CONTROLLED TRIAL TO TEST THE EFFICACY OF TRANS-TYMPANIC INJECTIONS OF A SODIUM THIOSULFATE GEL TO PREVENT CISPLATIN-INDUCED OTOTOXICITY IN PATIENTS WITH HEAD AND NECK CANCER — RECRUITING
• Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) — COMPLETED
• Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs — WITHDRAWN
• Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District — OTHER · PHASE2
• Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer — COMPLETED · PHASE1
• Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) — COMPLETED · PHASE1
• THE BURAN STUDY OF BUPARLISIB (AN2025) IN COMBINATION WITH PACLITAXEL COMPARED TO PACLITAXEL ALONE, IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA. — COMPLETED
• Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer — WITHDRAWN · PHASE2
• A PHASE 1B/2, OPEN-LABEL, MULTICENTRE STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOUR ACTIVITY OF MEDI4736 IN COMBINATION WITH AZD9150 OR AZD5069 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES AND SUBSEQUENTLY COMPARING AZD9150 AND AZD5069 BOTH AS MONOTHERAPY AND IN COMBINATION WITH MEDI4736 AS SECOND LINE TREATMENT IN PATIENTS WITH RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK — NOT_YET_RECRUITING · PHASE1
• M4OC-PREVENT: METFORMIN FOR ORAL CANCER PREVENTION — COMPLETED
• Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck — TERMINATED · PHASE2
• Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) — COMPLETED · PHASE2
• A RANDOMIZED PHASE II TRIAL OF CISPLATIN WITH OR WITHOUT WEE1 KINASE INHIBITOR MK-1775 FOR FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC SQUAMOUS CELL CANCER OF THE HEAD AND NECK (RM-SCCHN) — COMPLETED · PHASE2
• Phase II Trial of Allovectin-7® for Head and Neck Cancer — COMPLETED · PHASE3

Refine this search